Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Nuclear Cardiology
Published in: Journal of Nuclear Cardiology 2/2023

27-01-2022 | Sarcoidosis | Case Presentation Corner

18F-FDG/13N-ammonia cardiac PET findings in ATTR cardiac amyloidosis

Authors: Kathleen A. Young, MD, Melissa Lyle, MD, Andrew N. Rosenbaum, MD, Ian C. Chang, MD, Grace Lin, MD, Melanie C. Bois, MD, Omar F. Abou Ezzeddine, MD, CM, MS, Hayan Jouni, MD, Panithaya Chareonthaitawee, MD, Suraj Kapa, MD, Martha Grogan, MD, Leslie T. Cooper, MD, Lori Blauwet, MD, John P. Bois, MD

Published in: Journal of Nuclear Cardiology | Issue 2/2023

Login to get access

Abstract

18F-flurodeoxyglycose (FDG)/13N-ammonia positron emission tomography/computed tomography (PET/CT) is frequently utilized to evaluate cardiac sarcoidosis (CS) but findings can reflect other forms of myocardial inflammation or altered myocardial metabolic activity. Herein, we present five cases where cardiac PET findings suggested CS, but right ventricular endomyocardial biopsy samples revealed ATTR-type cardiac amyloidosis.
Literature
1.
Bois JP, Muser D, Chareonthaitawee P. PET/CT evaluation of cardiac sarcoidosis. PET Clin 2019;14:223‐32.CrossRefPubMed
2.
Chareonthaitawee P, Beanlands RS, Chen W, Dorbala S, Miller EJ, Murthy VL. Joint SNMMI-ASNC expert consensus document on the role of (18)F-FDG PET/CT in cardiac sarcoid detection and therapy monitoring. J Nucl Med 2017;58:1341‐53.CrossRefPubMedPubMedCentral
3.
Birnie DH, Sauer WH, Bogun F, Cooper JM, Culver DA, Duvernoy CS, et al. HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. Heart Rhythm 2014;11:1305‐23.CrossRefPubMed
4.
Terasaki F, Azuma A, Anzai T, Ishizaka N, Ishida Y, Isobe M, et al. JCS 2016 guideline on diagnosis and treatment of cardiac sarcoidosis-digest version. Circ J 2019;83:2329‐88.CrossRefPubMed
5.
Elwazir MY, Bois JP, Abou Ezzeddine OF, Chareonthaitawee P. Imaging and quantification of cardiac sarcoidosis. Semin Nucl Med 2020;50:283‐94.CrossRefPubMed
6.
Ruberg FL, Grogan M, Hanna M, Kelly JW, Maurer MS. Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review. J Am Coll Cardiol 2019;73:2872‐91.CrossRefPubMedPubMedCentral
7.
Dasari S, Theis JD, Vrana JA, Rech KL, Dao LN, Howard MT, et al. Amyloid typing by mass spectrometry in clinical practice: A comprehensive review of 16,175 samples. Mayo Clin Proc 2020;95:1852‐64.CrossRefPubMed
8.
Vaidya VR, Abudan AA, Vasudevan K, Shantha G, Cooper LT, Kapa S, et al. The efficacy and safety of electroanatomic mapping-guided endomyocardial biopsy: A systematic review. J Interv Card Electrophysiol 2018;53:63‐71.CrossRefPubMed
9.
Mohammed SF, Mirzoyev SA, Edwards WD, Dogan A, Grogan DR, Dunlay SM, et al. Left ventricular amyloid deposition in patients with heart failure and preserved ejection fraction. JACC Heart Fail 2014;2:113‐22.CrossRefPubMedPubMedCentral
10.
Siegismund CS, Escher F, Lassner D, Kuhl U, Gross U, Fruhwald F, et al. Intramyocardial inflammation predicts adverse outcome in patients with cardiac AL amyloidosis. Eur J Heart Fail 2018;20:751‐7.CrossRefPubMed
Metadata
Title
18F-FDG/13N-ammonia cardiac PET findings in ATTR cardiac amyloidosis
Authors
Kathleen A. Young, MD
Melissa Lyle, MD
Andrew N. Rosenbaum, MD
Ian C. Chang, MD
Grace Lin, MD
Melanie C. Bois, MD
Omar F. Abou Ezzeddine, MD, CM, MS
Hayan Jouni, MD
Panithaya Chareonthaitawee, MD
Suraj Kapa, MD
Martha Grogan, MD
Leslie T. Cooper, MD
Lori Blauwet, MD
John P. Bois, MD
Publication date
27-01-2022
Publisher
Springer International Publishing
Published in
Journal of Nuclear Cardiology / Issue 2/2023
Print ISSN: 1071-3581
Electronic ISSN: 1532-6551
DOI
https://doi.org/10.1007/s12350-021-02886-2

Other articles of this Issue 2/2023

Journal of Nuclear Cardiology 2/2023 Go to the issue

Original Article

Usefulness of the Vall d’Hebron Risk Score to stratify the risk of patients with ischemic cardiomyopathy

Images that Teach

Diagnosis of unrecognized aortic dissection by hybrid PET/CT rubidium-82 imaging

INFORMATION STATEMENT

Quality metrics for single-photon emission computed tomography myocardial perfusion imaging: an ASNC information statement

Theme Articles

Integration of coronary artery calcium scoring from CT attenuation scans by machine learning improves prediction of adverse cardiovascular events in patients undergoing SPECT/CT myocardial perfusion imaging

ASNC PRESIDENT’S MESSAGE

30 years of innovation: are you ready for a challenge?

Editorial

Unfolding the cardioprotective potential of sigma-1 receptor-directed molecular imaging

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits